Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Jaime Ramos-CejudoDepartment of Psychiatry, NYU Grossman School of Medicine, New York.ORCID 0000-0002-0993-9909
Alexa S BeiserDepartment of Biostatistics, Boston University School of Public Health, MA.ORCID 0000-0001-8551-7778
Sophia LuDepartment of Biostatistics, Boston University School of Public Health, MA.ORCID 0000-0002-2002-9818
Jeremy A TannerGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio.ORCID 0000-0001-9828-1776
Matthew R ScottDepartment of Biostatistics, Boston University School of Public Health, MA.
Tianshe HeDepartment of Psychiatry, NYU Grossman School of Medicine, New York.ORCID 0000-0001-9752-1256
Keith A JohnsonDepartments of Radiology and Neurology, Harvard Medical School, Boston, MA.ORCID 0000-0002-5916-6043
Joel SalinasDepartment of Neurology, NYU Grossman School of Medicine, New York.ORCID 0000-0002-3735-0018
Omonigho M BubuDepartment of Psychiatry, NYU Grossman School of Medicine, New York.
Els FieremansDepartment of Radiology, NYU Grossman School of Medicine, New York.
Antonio ConvitDepartment of Psychiatry, NYU Grossman School of Medicine, New York.
Nunzio PomaraDepartment of Psychiatry, NYU Grossman School of Medicine, New York.
Thomas WisniewskiDepartment of Psychiatry, NYU Grossman School of Medicine, New York.ORCID 0000-0002-3379-8966
Jeffrey S BergerDepartments of Medicine and Surgery, NYU Grossman School of Medicine, New York.
Ricardo S OsorioDepartment of Psychiatry, NYU Grossman School of Medicine, New York.
Charles S DecarliIDeA Laboratory, Department of Neurology, UC Davis, CA; and.ORCID 0000-0003-1914-2693
Andrew D JohnsonThe Framingham Study, Boston, MA.
Sudha SeshadriDepartment of Neurology, Boston University Chobanian & Avedisian School of Medicine, MA.ORCID 0000-0001-6135-2622
Funding
FRAMINGHAM HEART STUDY - YEAR 5 EXAM75N92019D00031 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · 2019 to 2024
$29.8M
Research Education ComponentP30AG066512 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Mary Sherman Mittelman · 2020 to 2026
$28.4M
South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Sudha Seshadri · 2021 to 2026
$24.0M
PRECURSORS OF STROKE INCIDENCE AND PROGNOSISR01NS017950 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Hugo Javier Aparicio, Jose Rafael Romero · 1985 to 2026
$22.9M
TR&D 4: Revealing Microstructure: Biophysical modeling and validation for discovery and clinical careP41EB017183 · NIBIB · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Daniel K Sodickson · 2014 to 2026
$19.3M
MRI, Genetics &Cognitive Precursors of AD &DementiaR01AG016495 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA · 1999 to 2016
$12.5M
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham CohortsR01AG054076 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DECARLI, CHARLES, SESHADRI, SUDHA · 2016 to 2020
$12.3M
FRAMINGHAM HEART STUDY (FHS), TASK AREA B - PROTOCOL DEVELOPMENT AND BASIC EXAMINATION75N92025D00012 · NHLBI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI LLOYD-JONES, DONALD · 2025 to 2025
$8.9M
Using a Health Disparity Research Framework to examine mechanisms linking Obstructive Sleep Apnea with higher Alzheimer’s disease risk in older Blacks/African-AmericansR01AG082278 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OMONIGHO A MICHAEL Bubu · 2023 to 2026
$6.9M
Cognitively Healthy Nonagenarians in the Cross Cohort Collaboration (CCC)R01AG059421 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Stephanie Anne-Carine Debette, Carole Dufouil · 2026 to 2026
$4.7M
Treatment of OSA on sleep-dependent memory and blood biomarkers in blacksRF1AG083975 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI OMONIGHO A MICHAEL Bubu, Korey Kam · 2023 to 2026
$4.2M
Depression treatment and Aβ dynamics: A study of Alzheimer’s disease riskR01AG070821 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI POMARA, NUNZIO · 2021 to 2025
objectivesVascular dysfunction contributes to Alzheimer disease (AD) and related dementias (ADRDs), but the underlying mechanisms remain unclear. Previous studies link midlife hemostasis and platelet aggregation measures to late-life dementia risk. We aimed to determine whether platelet aggregation in midlife is associated with imaging markers of AD pathology.
methodsIn a cross-sectional study, we evaluated associations between platelet aggregation, measured by light transmission aggregometry, and amyloid (
resultsPlatelet aggregation response was evaluated in 382 participants (mean age 56 ± 8 years, 53% female) approximately 1.2-1.5 years before amyloid and tau PET imaging. MRI data used for the AD signature were acquired together with PET imaging or within several months. The aggregation response exhibited a nonlinear association with AD pathology. Among those in the lowest tertile of adenosine diphosphate (ADP) response, platelet aggregation response was positively associated with increased amyloid in the precuneus (β = 0.047, DISCUSSION: Our findings indicate that platelet aggregation is linked to PET and MRI markers of AD pathology as early as midlife. These findings support further investigation of platelet-mediated mechanisms in AD pathogenesis.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Association of Platelet Aggregation With Markers of Alzheimer Disease Pathology in Middle-Aged Participants of the Framingham Heart Study. · full record | Socratic